Jan Boesen
Fondateur chez Middenduin Life Sciences BV
Profil
Jan Boesen is the founder of Middenduin Life Sciences BV.
He previously worked as the Co-Chief Executive Officer at IBL International GmbH from 2009 to 2013.
He also served as the Managing Director at BioConnection BV, Principal at Introgene BV and Amsterdam Molecular Therapeutics (AMT) Holding NV, and Chief Operating Officer at ISA Pharmaceuticals BV.
Dr. Boesen holds a doctorate degree from the University of Leiden and an undergraduate degree from Wageningen University.
Postes actifs de Jan Boesen
| Sociétés | Poste | Début |
|---|---|---|
| Middenduin Life Sciences BV | Fondateur | 30/07/2009 |
Anciens postes connus de Jan Boesen
| Sociétés | Poste | Fin |
|---|---|---|
IBL International GmbH
 IBL International GmbH Miscellaneous Commercial ServicesCommercial Services IBL International GmbH develops and produces products for the medical-diagnostics laboratories. The company provides research services in the fields of enzyme, radio and luminescence immunoassays. The firm provides products in the diagnostic fields of Endocrinology, Catecholamines, Neuroscience, Tumormarkers, Hypertension, Cytokines, Adhesion Molecules, Autoimmunity, Immunology and Infectious Diseases. IBL International was founded in 1983 and is headquartered in Hamburg, Germany. | Directeur Général | - |
| Introgene BV | Corporate Officer/Principal | - |
ISA Pharmaceuticals BV
 ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Directeur des opérations | - |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Corporate Officer/Principal | - |
BioConnection BV
 BioConnection BV BiotechnologyHealth Technology BioConnection BV manufactures and develops injectable pharmaceutical products. Its services include fill & finish, freeze drying, clinical trial material services, project management and consultancy services. The company was founded in 2005 and is headquartered in Oss, the Netherlands. | President | - |
Formation de Jan Boesen
| University of Leiden | Doctorate Degree |
| Wageningen University | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 6 |
|---|---|
BioConnection BV
BioConnection BV BiotechnologyHealth Technology BioConnection BV manufactures and develops injectable pharmaceutical products. Its services include fill & finish, freeze drying, clinical trial material services, project management and consultancy services. The company was founded in 2005 and is headquartered in Oss, the Netherlands. | Health Technology |
ISA Pharmaceuticals BV
ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Health Technology |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
| Introgene BV | Health Technology |
IBL International GmbH
IBL International GmbH Miscellaneous Commercial ServicesCommercial Services IBL International GmbH develops and produces products for the medical-diagnostics laboratories. The company provides research services in the fields of enzyme, radio and luminescence immunoassays. The firm provides products in the diagnostic fields of Endocrinology, Catecholamines, Neuroscience, Tumormarkers, Hypertension, Cytokines, Adhesion Molecules, Autoimmunity, Immunology and Infectious Diseases. IBL International was founded in 1983 and is headquartered in Hamburg, Germany. | Commercial Services |
| Middenduin Life Sciences BV |
